Boehringer Ingelheim’s Jascayd (nerandomilast) tablets have been granted marketing authorisation by the Medicines and ...
Ipsen is set to acquire Memo Therapeutics in a deal worth more than €700m EUR that is focused on potravitug, a phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results